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ContracturesA B S T R A C T
Background: Mycobacterium ulcerans (MU) produces mycolactone toxin when infected with a
plasmid. Toxin is cytotoxic and immunosuppressive, causing extensive destruction of tis-
sues, leading to large ulcers on exposed parts of the body. Spontaneous healing by sec-
ondary intention leads to contractures, subluxation of joints, disuse atrophy, distal
lymphedema and other complications. The disease is endemic in some communities
within the middle belt of Ghana.
Objective: To document the clinical and epidemiological features of MU disease in the mid-
dle belt of Ghana and the outcome of treatment.
Patients and methods: Patients with lesions suspected to MU disease were screened by com-
munity workers. Lesions were confirmed by any of the following: direct smear examina-
tion, culture, polymerase chain reaction (PCR), or histopathology.
Patients were treated with rifampicin (10 mg/kg orally) and streptomycin (15 mg/kg IM)
combination for eight weeks. Patients selected for surgical treatment included cases where
medical treatment had failed, cases where medical treatment is contraindicated, cases pre-
senting late with complications and recurrent cases.
Results: 258 patients were seen in the Ahafo Ano, Amansie Central, Amansie West, Asu-
nafo, Asutifi, and Upper Denkyira districts of Ghana between 2005 and 2012. Their ages ran-
ged from 1 year 3 months to 98 years, with a mean age of 29.8 (SD 20.4).
The clinical forms of MU disease seen were: papule (0.5%), nodule (1.5%), chronic
osteomyelitis (1.5%), contracture (1.5%), edematous lesion (3%), and ulcer (92%). Uncommon
complications include subluxation of knee joint, salivary gland fistula and Marjolin’s ulcer.
The lesions were distributed as follows: head and neck (6.8%), upper limb (20.3%), trunk
(1.7%), and lower limb (71.2%).
Conclusion: MU disease in themiddle belt of Ghana can be controlled by early case detection
and adequate curative treatment.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.
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endemic community.
Fig. 2 – A nodule on the upper arm of a 9-year-old boy in a
BU-endemic community.
Fig. 3 – Typical Buruli ulcers on the cervical and sub-mental
regions of an 8-year-old girl.Introduction
Mycobacterium ulcerans (Buruli ulcer) disease occurs most fre-
quently in tropical and subtropical areas that are marshy or
near lakes and rivers. The disease has been reported world-
wide from Australia, Japan, Papua New Guinea and China.
Benin, Cote d’Ivoire and Ghana are the most endemic coun-
tries in Africa [1]. Cases in Ghana were identified in all 10
regions, and in 90 (81.8%) of the then-110 districts in a
national case search in 1999 [2]. Some of the districts known
to be endemic in Ghana include Ahafo Ano, Amansie Central,
Amansie West, Asunafo, Asutifi, and Upper Denkyira [3,4].
These communities are found in Ashanti, Brong Ahafo, and
Central regions. They form part of the middle belt of Ghana,
which has rain forest as the vegetative cover. The middle belt
is drained by several rivers, some of which enter the sea
directly or are tributaries of rivers entering the sea. In addi-
tion, there is an inland lake in Ashanti. Six communities in
the drainage area of Tano (Ahafo Ano, Asunafo, and Asutifi)
and Offin (Amansie Central, Amansie West, and Upper
Denkyira) rivers were the setting for the current study.
The etiological agent of Buruli ulcer (BU) disease isM. ulcer-
ans (MU), an acid fast bacillus, which can be cultured on
Lowenstein Jensen medium at a temperature of 30 C–33 C
[5]. Analysis of its complete genome sequence has revealed
the presence of a set of three large genes which is responsible
for the production of mycolactone [1], a toxin which has cyto-
toxic and immunosuppressive properties [6]. This toxin is
produced when the MU is infected with a transmissible plas-
mid [7]. This toxin is mainly responsible for the pathology of
MU disease [8]. Infection with MU often leads to extensive
destruction of tissue with the formation of large ulcers, espe-
cially on the limbs and other exposed parts of the body, such
as the head and neck [9]. Spontaneous healing of the ulcers
may occur, but may lead to considerable deformity, such as
contractures, subluxation of joints, disuse atrophy, and distal
lymphedema [5]. The mode of transmission of MU disease is
not known, though MU has been found in biofilms, soil, aqua-
tic insects, water bugs, fish and wildlife [10]. The disease is
classified into non-ulcerative and ulcerative forms [11]. The
non-ulcerative forms include the papule (Fig. 1), nodule
(Fig. 2), plaque and edematous forms. The ulcer typically
has undermined edges, indurated peripherally, and may have
white cotton wool-like slough (Fig. 3). The active MU lesion is
usually painless unless there is a secondary bacterial infec-
tion [5].
Initially surgical excision was the standard treatment, and
when performed at an early stage of the disease, was cura-
tive. Unfortunately, most patients present late with advanced
disease (Fig. 4), requiring wide surgical excision and skin
grafting, or occasional limb amputations [11]. The World
Health Organization (WHO) in March 2003 recommended
the daily administration of rifampicin and an aminoglycoside,
usually streptomycin, for eight weeks as the first-line treat-
ment for all forms of active MU disease. Surgery was recom-
mended to remove necrotic tissue, cover skin defects and
correct deformities. Interventions were to be instituted to pre-
vent or minimize disabilities [12].
Fig. 4 – Buruli ulcer on the lower limb of a 27-year-old farmer
requiring wide excision and skin grafting.
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cal and epidemiological features of MU disease in the six
endemic districts, within the period from January 2005 to
December 2012, and to assess the outcome of medical and
surgical treatment offered. This knowledge could help in
determining the disease pattern in the middle belt of
Ghana, and to determine the optimal treatment modality
for the disease in the Ghanaian situation based on WHO
recommendations.
Patients and methods
Community workers specially trained under the National
Buruli Ulcer Control Program identify patients with all forms
of MU disease in the endemic communities. These are
referred to the district hospitals where they are examined
clinically by the doctor and the diagnosis confirmed by direct
smear and microscopy of tissues from lesions, culture on
Lowenstein Jensen medium, histopathology of tissue
obtained at surgery or polymerase chain reaction (PCR). The
latter two tests could only be done at Komfo Anokye
Teaching Hospital or the Kumasi Centre for Collaborative
Research (KCCR) into Tropical Medicine.
Confirmed active cases were treated with intramuscular
streptomycin (15 mg/kg) and oral rifampicin (10 mg/kg) in
combination for eight weeks. Patients selected for surgery
include those with unhealed lesions after completion of
antibiotic treatment, those in whom medical treatment had
failed, those in whom medical treatment is contraindicated
and those presenting with complications of MU disease.
Patients were included in the study if they were treated for
MU disease between the period from January 2005 to
December 2012; their diagnoses of MU disease have been con-
firmed by any of the above 4 tests; have completed 8 weeks of
streptomycin and rifampicin combination; and/or undergone
surgery for MU disease or its complications.
Ethical approval for the study was obtained from the
Committee on Human Research Publication and Ethics
(CHRPE) of Kwame Nkrumah University of Science and
Technology in Kumasi. All the patients or their parents, inthe case of children, consented to participate in the study.
They also consented to the use of their clinical pictures for
teaching purposes and for the dissemination of knowledge
of MU disease.
Results
A total of 518 patients were seen at Ahafo Ano, Amansie
Central, Amansie West, Asunafo, Asutifi, and Upper
Denkyira districts of Ghana from 2005 to 2012. Their ages ran-
ged from 1 year 3 months to 98 years; the mean age was 29.8
(SD = 20.4).
The distribution of the MU lesions on the body were as fol-
lows: head and neck (6.8%), upper limbs (20.3%), trunk (1.7%)
and lower limbs (71.2%). The clinical forms of the disease
were as follows: papule (0.5%), nodule (1.5%), edematous
lesion (3%), ulcer (92%), osteomyelitis (1.5%) and contracture
(1.5%). There were three uncommon complications: subluxa-
tion of knee joint (one case), salivary gland fistula (one case),
and Marjolin’s ulcer (one case).
260 patients were treated solely with streptomycin and
rifampicin, and their lesions healed completely; they did not
require any surgery (Figs. 5a–d). 258 patients either had
antibiotics and surgery, or had surgery alone. The types of
surgical procedures performed are shown in Table 1.
Discussion
Even though the mode of transmission of the disease is not
precisely known, the distribution of the lesions in this study,
with a higher concentration on the limbs, especially the lower
limbs (71.2%), and the head and neck region of children (6.8%)
(Fig. 3), supports the findings of other workers [2,9,10,16] that
MU is an environmental pathogen, transmitted probably close
to the ground, in an aquatic environment, such as prevails in
the middle belt of Ghana.
Most of the MU lesions (92%) were ulcers, requiring exci-
sion and skin grafting (71%) after antibiotic treatment. The
earlier clinical forms of the disease, such as the papule
(0.5%), the nodule (1.5%) and the edematous lesion (3%),
which can be cured either by surgery or by antibiotics, appear
to be fewer in this series. These lesions can easily be mis-
taken for reactions to insect bites, allergic reactions, or minor
injuries common in the environment. Pure MU lesions are
generally painless, unless there is secondary bacterial infec-
tion [5]; hence, such cases are likely to be ignored by the
patients. Inexperienced field workers may also not consider
such lesions to be due to MU disease, thus explaining the rar-
ity of the early stages.
The efficacy of streptomycin/rifampicin combination in
the treatment of MU disease has been demonstrated in sev-
eral series [13,14] and in Fig. 5. When instituted early in
active disease, the antibiotic combination may limit the
extent of, or obviate the need for surgery. The combination
of surgery and antibiotics provides optimal results in the
management of MU disease [15]. However, for patients pre-
senting with contractures, surgery remains the main option
since antibiotics have no role in a situation where there are
no organisms.
Fig. 5 – Effect of streptomycin/rifampicin therapy for MU disease of the face.
Table 1 – Surgical procedures performed for 258 patients with MU disease.
Surgical procedure Percentage (%)
Wound excision and skin grafting 71
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The middle belt of Ghana provides an ideal environment for
M. ulcerans disease to thrive. Eradication of the disease would
involve breaking the cycle of transmission, which is currently
not precisely known. Adequate control can, however, be
achieved by detecting the disease at an early stage where
curative treatment can be offered.
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